{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T10:42:33Z","timestamp":1794998553890,"version":"4.9.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000156","name":"Sant\u00e9","doi-asserted-by":"publisher","award":["366391"],"award-info":[{"award-number":["366391"]}],"id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011094","name":"Public Health Agency of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011094","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["NPC-178912"],"award-info":[{"award-number":["NPC-178912"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.clinre.2025.102639","type":"journal-article","created":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T02:00:17Z","timestamp":1750039217000},"page":"102639","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Metabolic factors drive early increase in hepatic steatosis despite improvement in non-invasive fibrosis markers after hepatitis C eradication with direct-acting antivirals"],"prefix":"10.1016","volume":"49","author":[{"given":"Mohamed","family":"Shengir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesal","family":"Elgretli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felice","family":"Cinque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnihotram V.","family":"Ramanakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Cespiati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Ludovica","family":"Fracanzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luz","family":"Ballesteros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Deschenes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2655-8283","authenticated-orcid":false,"given":"Giada","family":"Sebastiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.clinre.2025.102639_bib0002","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S2468-1253(21)00472-6","article-title":"Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study","volume":"7","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.clinre.2025.102639_bib0003","doi-asserted-by":"crossref","first-page":"120","DOI":"10.4254\/wjh.v5.i3.120","article-title":"Severe adverse events during antiviral therapy in hepatitis C virus cirrhotic patients: a systematic review","volume":"5","author":"Bota","year":"2013","journal-title":"World J Hepatol"},{"issue":"5","key":"10.1016\/j.clinre.2025.102639_bib0004","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1542-3565(04)00018-7","article-title":"Effectiveness of interferon alpha-2b and ribavirin combination therapy in the treatment of naive chronic hepatitis C patients in clinical practice","volume":"2","author":"Shehab","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"13","key":"10.1016\/j.clinre.2025.102639_bib0005","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.clinre.2025.102639_bib0006","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s00535-024-02101-2","article-title":"Dynamic change of metabolic dysfunction-associated steatotic liver disease in patients with hepatitis C virus infection after achieving sustained virologic response with direct-acting antivirals","volume":"59","author":"Liu","year":"2024","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.clinre.2025.102639_bib0007","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciad319","article-title":"Hepatitis C Guidance 2023 update: AASLD-IDSA recommendations for testing, managing, and treating Hepatitis C Virus infection","author":"Bhattacharya","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.clinre.2025.102639_bib0008","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1111\/jvh.12965","article-title":"Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of health-related quality of life in East Asian patients with hepatitis C virus infection","volume":"25","author":"Younossi","year":"2018","journal-title":"J Viral Hepat"},{"issue":"1","key":"10.1016\/j.clinre.2025.102639_bib0009","doi-asserted-by":"crossref","first-page":"62","DOI":"10.4254\/wjh.v14.i1.62","article-title":"Hepatitis C: problems to extinction and residual hepatic and extrahepatic lesions after sustained virological response","volume":"14","author":"Cuesta-Sancho","year":"2022","journal-title":"World J Hepatol"},{"issue":"4","key":"10.1016\/j.clinre.2025.102639_bib0010","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jhep.2020.11.040","article-title":"Residual risk of liver disease after hepatitis C virus eradication","volume":"74","author":"Negro","year":"2021","journal-title":"J Hepatol"},{"issue":"1 Suppl","key":"10.1016\/j.clinre.2025.102639_bib0011","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1016\/j.jhep.2016.08.001","article-title":"Management of the patient with SVR","volume":"65","author":"Terrault","year":"2016","journal-title":"J Hepatol"},{"issue":"11","key":"10.1016\/j.clinre.2025.102639_bib0012","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.3748\/wjg.v24.i11.1269","article-title":"Fatty liver in hepatitis C patients post-sustained virological response with direct-acting antivirals","volume":"24","author":"Noureddin","year":"2018","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.clinre.2025.102639_bib0013","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jceh.2018.06.009","article-title":"Therapy with oral directly acting agents in Hepatitis C infection is associated with reduction in fibrosis and increase in hepatic steatosis on transient elastography","volume":"9","author":"Rout","year":"2019","journal-title":"J Clin Exp Hepatol"},{"issue":"1","key":"10.1016\/j.clinre.2025.102639_bib0014","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.clinre.2025.102639_bib0015","doi-asserted-by":"crossref","first-page":"5562","DOI":"10.1038\/s41598-022-09588-w","article-title":"Infection with the hepatitis C virus causes viral genotype-specific differences in cholesterol metabolism and hepatic steatosis","volume":"12","author":"Sheridan","year":"2022","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.clinre.2025.102639_bib0016","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17060803","article-title":"NAFLD and NASH in HCV infection: prevalence and significance in hepatic and extrahepatic manifestations","volume":"17","author":"Adinolfi","year":"2016","journal-title":"Int J Mol Sci"},{"issue":"41","key":"10.1016\/j.clinre.2025.102639_bib0017","doi-asserted-by":"crossref","first-page":"15233","DOI":"10.3748\/wjg.v20.i41.15233","article-title":"Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3","volume":"20","author":"Abenavoli","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.clinre.2025.102639_bib0018","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.tim.2010.11.005","article-title":"Assembly of infectious hepatitis C virus particles","volume":"19","author":"Bartenschlager","year":"2011","journal-title":"Trends Microbiol"},{"issue":"6","key":"10.1016\/j.clinre.2025.102639_bib0019","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.tem.2011.03.004","article-title":"Unique ties between hepatitis C virus replication and intracellular lipids","volume":"22","author":"Herker","year":"2011","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.clinre.2025.102639_bib0020","article-title":"A multi-society Delphi consensus statement on new fatty liver disease nomenclature","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.clinre.2025.102639_bib0021","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.clinre.2025.102639_bib0022","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jhep.2024.09.038","article-title":"Risk of de novo HCC in patients with MASLD following direct-acting antiviral-induced cure of HCV infection","volume":"82","author":"Liu","year":"2025","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.clinre.2025.102639_bib0023","doi-asserted-by":"crossref","DOI":"10.1111\/jvh.70004","article-title":"Association of MASLD phenotypes with liver fibrosis in Hepatitis C: the role of cardiometabolic risk factors","volume":"32","author":"Elgretli","year":"2025","journal-title":"J Viral Hepat"},{"issue":"1","key":"10.1016\/j.clinre.2025.102639_bib0024","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.clinre.2025.102639_bib0025","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2893.2011.01534.x","article-title":"Novel controlled attenuation parameter for non-invasive assessment of steatosis using Fibroscan (\u00ae): validation in chronic hepatitis C","volume":"19","author":"Sasso","year":"2012","journal-title":"J Viral Hepat"},{"issue":"5","key":"10.1016\/j.clinre.2025.102639_bib0026","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jhep.2016.12.022","article-title":"Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis","volume":"66","author":"Karlas","year":"2017","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.clinre.2025.102639_bib0027","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update","volume":"75","year":"2021","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.clinre.2025.102639_bib0028","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2015.04.006","article-title":"EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis","volume":"63","year":"2015","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.clinre.2025.102639_bib0029","first-page":"3104","article-title":"The diagnostic utility of FIB-4 as a non-invasive tool for liver fibrosis scoring among NAFLD patients: a retrospective cross-sectional study","volume":"28","author":"Amer","year":"2024","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"6","key":"10.1016\/j.clinre.2025.102639_bib0030","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple non-invasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.clinre.2025.102639_bib0031","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The strengthening the reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"issue":"24","key":"10.1016\/j.clinre.2025.102639_bib0032","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis","volume":"308","author":"van der Meer","year":"2012","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.clinre.2025.102639_bib0033","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1002\/hep4.1228","article-title":"Morphometry confirms fibrosis regression from sustained virologic response to direct-acting antivirals for Hepatitis C","volume":"2","author":"Pan","year":"2018","journal-title":"Hepatol Commun"},{"issue":"2","key":"10.1016\/j.clinre.2025.102639_bib0034","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00535-024-02165-0","article-title":"Histological improvement of fibrosis in patients with hepatitis C who achieved a 5-year sustained virological response to treatment with direct-acting antivirals","volume":"60","author":"Iwamoto","year":"2025","journal-title":"J Gastroenterol"},{"issue":"1","key":"10.1016\/j.clinre.2025.102639_bib0035","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1159\/000282105","article-title":"Hepatitis C virus-induced steatosis: an overview","volume":"28","author":"Negro","year":"2010","journal-title":"Dig Dis"},{"issue":"10","key":"10.1016\/j.clinre.2025.102639_bib0036","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.dld.2020.11.001","article-title":"Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): evaluation by the controlled attenuation parameter (CAP)","volume":"53","author":"Cespiati","year":"2021","journal-title":"Dig Liver Dis"},{"issue":"2","key":"10.1016\/j.clinre.2025.102639_bib0037","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/jmv.24950","article-title":"Serial changes in liver stiffness and controlled attenuation parameter following direct-acting antiviral therapy against hepatitis C virus genotype 1b","volume":"90","author":"Ogasawara","year":"2018","journal-title":"J Med Virol"},{"issue":"4","key":"10.1016\/j.clinre.2025.102639_bib0038","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/hep.27844","article-title":"The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease","volume":"62","author":"Petta","year":"2015","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.clinre.2025.102639_bib0039","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jhep.2013.04.027","article-title":"A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver","volume":"59","author":"Pais","year":"2013","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.clinre.2025.102639_bib0040","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but No other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty Liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.clinre.2025.102639_bib0041","doi-asserted-by":"crossref","first-page":"7845","DOI":"10.1038\/s41598-018-26293-9","article-title":"Eradication of hepatitis C virus is associated with the attenuation of steatosis as evaluated using a controlled attenuation parameter","volume":"8","author":"Shimizu","year":"2018","journal-title":"Sci Rep"},{"issue":"9","key":"10.1016\/j.clinre.2025.102639_bib0042","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0163644","article-title":"Rapid increase in serum low-density lipoprotein cholesterol concentration during Hepatitis C interferon-free treatment","volume":"11","author":"Hashimoto","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.clinre.2025.102639_bib0043","doi-asserted-by":"crossref","first-page":"64","DOI":"10.5604\/01.3001.0010.7536","article-title":"Worsening of serum lipid profile after direct acting antiviral treatment","volume":"17","author":"Gitto","year":"2018","journal-title":"Ann Hepatol"},{"issue":"12","key":"10.1016\/j.clinre.2025.102639_bib0044","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0209216","article-title":"Improvement of insulin sensitivity in diabetic and non diabetic patients with chronic hepatitis C treated with direct antiviral agents","volume":"13","author":"Gualerzi","year":"2018","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.clinre.2025.102639_bib0045","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12944-023-01957-2","article-title":"Effects of sustained viral response on lipid in Hepatitis C: a systematic review and meta-analysis","volume":"23","author":"Mei","year":"2024","journal-title":"Lipids Health Dis"},{"issue":"23","key":"10.1016\/j.clinre.2025.102639_bib0046","doi-asserted-by":"crossref","first-page":"7089","DOI":"10.3748\/wjg.v20.i23.7089","article-title":"Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen","volume":"20","author":"Lonardo","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"6","key":"10.1016\/j.clinre.2025.102639_bib0047","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.3390\/clinpract14060200","article-title":"Metabolic dysfunction-associated steatotic liver disease in chronic Hepatitis C Virus infection: from basics to clinical and nutritional management","volume":"14","author":"Gonzalez-Aldaco","year":"2024","journal-title":"Clin Pr"},{"issue":"7","key":"10.1016\/j.clinre.2025.102639_bib0048","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/hepr.13899","article-title":"Hepatitis C virus eradication by direct-acting antivirals causes a simultaneous increase in the prevalence of fatty liver and hyper low-density lipoprotein cholesterolemia without an increase in body weight","volume":"53","author":"Tokuchi","year":"2023","journal-title":"Hepatol Res"},{"issue":"2","key":"10.1016\/j.clinre.2025.102639_bib0049","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/hep.23312","article-title":"Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease","volume":"51","author":"Wong","year":"2010","journal-title":"Hepatology"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740125001160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740125001160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T15:11:16Z","timestamp":1754320276000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740125001160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":48,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2210740125001160"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2025.102639","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic factors drive early increase in hepatic steatosis despite improvement in non-invasive fibrosis markers after hepatitis C eradication with direct-acting antivirals","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2025.102639","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"102639"}}